Mabwell(SH:688062) Xin Lang Zheng Quan·2026-01-16 06:00Core Viewpoint - Maiwei Biotech's stock has shown volatility with a recent increase of 2.03%, but has experienced a decline of 6.71% over the past five trading days, indicating mixed market sentiment [1] Group 1: Stock Performance - As of January 16, Maiwei Biotech's stock price is 42.70 CNY per share, with a market capitalization of 17.063 billion CNY [1] - The stock has increased by 11.00% year-to-date, but has seen a decline of 4.37% over the past 60 days [1] - Trading volume on January 16 reached 2.31 million CNY, with a turnover rate of 2.71% [1] Group 2: Financial Performance - For the period from January to September 2025, Maiwei Biotech reported revenue of 566 million CNY, reflecting a year-on-year growth of 301.03% [2] - The company recorded a net profit attributable to shareholders of -598 million CNY, which is a year-on-year increase of 13.89% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders has increased by 9.15% to 19,600, while the average number of circulating shares per person has decreased by 8.38% to 10,425 shares [2] - Notable institutional shareholders include E Fund Medical Healthcare Industry Mixed A, which is the fourth largest shareholder with 3.1746 million shares, and South China CSI 1000 ETF, which is a new entrant among the top ten shareholders [2]